Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZYG24002
- Development stage
- Phase 1
- Lead developer
- Sinomune Pharmaceutical
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
ZYG24002 is a topical small molecule Janus kinase (JAK) inhibitor developed by Sinomune Pharmaceutical Co., Ltd. for the treatment of inflammatory skin conditions, primarily seborrheic dermatitis. By targeting the JAK-STAT signaling pathway, ZYG24002 aims to modulate the immune response and reduce the production of pro-inflammatory cytokines that drive the pathogenesis of seborrheic dermatitis, such as erythema and scaling. The drug is currently being evaluated in Phase 1b clinical trials (e.g., NCT06344104) as a lotion in various concentrations (0.5%, 0.75%, and 1.0%) to establish its safety, tolerability, pharmacokinetics, and preliminary efficacy in adult patients with mild to moderate disease.
- Other names
- ZYG24002 LotionZYG-24002 LotionZYG 24002 Lotion
Beyond the preview
Go deeper on ZYG24002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZYG24002.